Donislecel

Summary

Donislecel (CHEMBL4594332) is an approved cell (ATC A10XX02); indicated across 2 conditions including hypoglycemia and type 1 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Cell
• ATC class: A10XX02
• Indications: 2 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594332
Name	Donislecel
Type	Cell
Max phase	4
ATC	A10XX02

Also known as: Donislecel, Lantidra, DONISLECEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypoglycemia	4	MONDO:0004946	HP:0001943
type 1 diabetes mellitus	1	MONDO:0005147	MONDO:0005147

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).